Innovations to expand and accelerate the commercial impact of DNA modifications
Active Project Grant Awarded Last action
- Award ID
- R41HG013877
- Recipient
-
Dnali Data Technologies, Inc. UEI D1GNGHBC83Q6
- Awarding agency
-
National Human Genome Research Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $584,076
Award facts
- Assistance listing
- 93.350 National Center for Advancing Translational Sciences
- Completion date 92% complete
- Originally
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- Place of performance
- North Carolina, USA
Award details come from USAspending.gov.
Description
- Abstract
- Chemical modifications to synthetic DNA are of central importance to both: 1) understanding biology and disease and 2) enabling a wide range of biomedical applications and research tools. However, despite their importance, most modification patterns are not possible to make and those that are are exorbitantly expensive to synthesize (by at least 10X), in contrast to the rapidly dropping costs for unmodified DNA synthesis. The central challenge is that the most advanced methods to create modified DNA oligos continue to rely on phosphoramidite synthesis, an organic chemistry process that uses harsh reaction conditions that require expensive chemically protected monomers and associated deprotection steps, or that simply prohibits certain types of modified dnas from being synthesized at all. To address this challenge, we have developed a robust platform technology capable of pro- ducing chemically modified DNA. IT is technologically differentiated from the current state of the art through its use of sustainable enzymatic synthesis in mild and low temperature conditions, compatibility with a diverse range of modification types, and low cost and recycleable templates and reagents. The proposed work seeks to ad- vance the commercial potential of this technology by: aim I - creating modified DNA products that cannot be ordered from any existing vendor; aim II - developing an innovation on our technology that will eliminate the most costly reagent in our synthesis process, the biotinylated template; and aim III - establishing and mapping the breadth of modifications that our platform technology can incorporate into DNA oligos and their relative SYN- thesis efficiencies.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $85,000 | |
| Amendment | $249,538 | |
| Original award | $249,538 |
Quick answers
Who received award R41HG013877?
R41HG013877 was awarded to Dnali Data Technologies, Inc. by National Human Genome Research Institute (National Institutes of Health) on June 15, 2024.
How much is award R41HG013877 worth?
$584,076 has been obligated on R41HG013877.
Which agency awarded R41HG013877?
National Human Genome Research Institute (National Institutes of Health) awarded R41HG013877, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award